Nexvet charts Q1 loss, hires animal health veteran to lead development; Affymetrix strikes genomics deal with Zoetis; Kindred's Q1 loss widens;

> Nexvet ($NVET) reported that its net loss in the first quarter was $2.7 million, compared to $1.5 million in the same period a year ago. The company also hired former Eli Lilly ($LLY) and Novartis ($NVS) Animal Health executive Jürgen Horn as its chief product development officer. Earnings release | Hiring release

> Affymetrix ($AFFX) bought Eureka Genomics for $15 million and simultaneously formed a multiyear agreement to grant Zoetis ($ZTS) preferred rights to incorporate some of Eureka's technologies into its genomic products for cattle and sheep. Release

> Kindred Biosciences ($KIN) reported a first-quarter net loss of $6.7 million, or $0.34 per share, vs. a net loss of $6.2 million or $0.38 per share in the same quarter a year ago. Release

> Researchers at the University of Edinburgh published a study showing that higher levels of vitamin D were linked to better survival chances in hospitalized cats. Release

> Kane Biotech, a maker of biofilms for the human and animal health markets, announced that CEO Gord Froehlich has retired and been replaced by Mark Ahrens-Townsend. Release

> OC Raw Dog has recalled 2,055 pounds of its Turkey & Produce Raw Frozen Canine Formulation because of possible Salmonella contamination. Release

> Researchers at Washington State University's Paul G. Allen School for Global Animal Health have published a study showing a strong association between the number of illnesses among family members on Kenyan farms and the frequency of livestock sicknesses and deaths in the same household. Release